News

New investors Mubadala Capital and Exor Ventures spearheaded this oversubscribed round. The Series B extension also saw participation from Qatar Investment Authority, alongside current stakeholders including Abingworth and

This new treatment is specifically indicated as a monotherapy for paediatric patients aged one month to two years with IS, provided the potential benefits justify the risk of

This therapy is currently being developed to treat chronic myeloid leukemia (CML) as well as other hematological cancers. If Takeda exercises this option, the company will have the

The alliance will harness the potential of traditional medical compounds in the fight against bacterial infections. Quadram’s TraDIS-Xpress platform will be utilised to innovate antibacterial treatments by  studying

These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation

This partnership will focus on developing a translational medicine ecosystem and launching innovative research initiatives in Abu Dhabi. The second MoU outlines plans to design and develop a

This development follows the clearance for an investigational new drug (IND) application by the FDA for the asset last month. The fast track status is expected to expedite

A decision on the approval under the Prescription Drug User Fee Act (PDUFA) is anticipated on 25 January 2025. LEQEMBI is intended to treat AD patients having mild

The investment is managed by the funds of Permira and is expected to close by the fourth quarter of 2024, subject to necessary approvals and conditions. The companies